Health & Fitness
Fri, June 29, 2012Thu, June 28, 2012Wed, June 27, 2012Tue, June 26, 2012Mon, June 25, 2012Sun, June 24, 2012Sat, June 23, 2012Fri, June 22, 2012Thu, June 21, 2012Wed, June 20, 2012Tue, June 19, 2012Mon, June 18, 2012Sun, June 17, 2012Sat, June 16, 2012Fri, June 15, 2012Thu, June 14, 2012Wed, June 13, 2012Tue, June 12, 2012Mon, June 11, 2012Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
Published in Health and Fitness on Tuesday, June 19th 2012 at 5:35 GMT by Market Wire
Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day -- NEW YORK, June 19, 2012 /PRNewswire/ --
Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
NEW YORK, June 19, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: [ KERX ]) today announced that its upcoming Analyst Day will be webcast live on Thursday, June 21, 2012 at 4:30 pm ET. Scheduled speakers include:
Julia Lewis, M.D., will provide her perspective on the Zerenex (ferric citrate) Phase 3 clinical program and the potential Zerenex product profile.
-- Professor of Medicine, Division of Nephrology, Vanderbilt University School of Medicine.
Geoffrey Block, M.D., will discuss the potential for Zerenex in pre-dialysis.
-- Director of Research, Denver Nephrology and Associate Clinical Professor in Medicine, University of Colorado Health Sciences Center.
David Goldfarb, M.D., will discuss the potential importance of citrate.
-- Chief, Nephrology Division, NY Campus of NY Harbor Health Care Veterans Affairs System and Professor of Medicine & Physiology, NYU School of Medicine.
To access the live audio webcast, please visit the Company's Investor Relations section of their website ([ http://investors.keryx.com ]). An archived version of the webcast will become available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.
KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: [ lfischer@keryx.com ]
SOURCE Keryx Biopharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.keryx.com ]
